A nasal HPV vaccine has been shown to shrink cervical cancer tumors in mice, researchers reported in Science Translational Medicine last month. The vaccine targets HPV16 E7, a protein made by the human papillomavirus (HPV) that targets a tumor suppressor and causes uncontrolled cell growth. Unlike most vaccines, which are preventative, this medicine could be…
Scientists develop new machine-learning model to predict immunogenic neoantigens
Researchers at Cleveland Clinic’s Global Center for Immunotherapy, in collaboration with Bristol Myers Squibb, have published a comprehensive study on how the immune system remodels the tumor microenvironment in response to immune checkpoint therapy. This research represents the most detailed analysis of this process to date. Under the leadership of Timothy Chan, MD, PhD, Chair…

